Pharmaceuticals

Sito Bio

Sito Bio released FY2026 Q1 earnings on April 27 After-Market (BJT), actual revenue CNY 328.05 M, actual EPS CNY 0.02

Sito Bio FY2026 Q1 Earnings Release on April 28, After-Market (BJT)

Sito Bio FY2025 Annual Earnings Release on April 28 After-Market (BJT), Forecast Revenue CNY 1.538 B, EPS CNY 0.39

Sito Bio released FY2025 Q3 earnings on October 28 After-Market (BJT), actual revenue CNY 241.43 M, actual EPS CNY -0.0824

Sito Bio released FY2025 9 Months earnings on October 28 After-Market (BJT), actual revenue CNY 749.19M, actual EPS CNY -0.3629

Sito Bio to Release FY2025 Q3 Earnings on October 29 After-Market (BJT)

Sito Bio released FY2025 semi-annual earnings on August 25 During-Market (BJT), actual revenue CNY 507.76 M, actual EPS CNY -0.28

Sito Bio released FY2025 Q2 earnings on August 25 During-Market (BJT), actual revenue CNY 247.91 M, actual EPS CNY -0.1304

Sito Bio to Release FY2025 Semi-Annual Earnings on August 26, 2025 (BJT)

Seto Bio subsidiary receives GMP compliance notification

Sireya Pharmaceutical, subsidiary of Saitebo Bio, Receives CEP Certificate from EDQM

Shandong Sre Pharmaceutical Obtains CEP Certificate for Dexamethasone API

Sito Bio released FY2024 Q4 earnings on April 28 After-Market BJT, actual revenue CNY 205.57 M, actual EPS CNY -0.5081

Sito Bio released FY2024 earnings on April 28 After-Market (BJT), actual revenue CNY 970.6 M (forecast CNY 1.404 B), actual EPS CNY -0.47 (forecast CNY 0.3)

Sito Bio released FY2025 Q1 earnings on April 28 After-Market BJT, actual revenue CNY 259.85 M, actual EPS CNY -0.15

Sito Bio to Release FY2025 Q1 Earnings Report on April 29 After-Market BJT

Sito Bio to release FY2024 earnings on April 29 After-Market (BJT), forecast revenue CNY 1.404 B, EPS CNY 0.3

Saito Bio Expects Net Profit Loss of 70 Million to 100 Million in 2024

Saito Bio's Subsidiary Receives Approval for Triamcinolone Listing

Seto Biology releases Q3 2024 report

300583

36Kr learned that Sito Bio announced plans to repurchase company shares through centralized bidding, with a total repurchase amount not less than 15 million yuan and not exceeding 30 million yuan. The repurchase price will not exceed 21.98 yuan per share. The repurchased shares will be used for employee stock ownership plans or equity incentives. The repurchase period is within 12 months from the date the board of directors approves the share repurchase plan

36Kr

Sito Bio: Plans to repurchase company shares for 15 million to 30 million yuan

Sito Bio's holding subsidiary, Shandong Sray Pharmaceutical Co., Ltd., recently received approval from the National Medical Products Administration for the marketing application of methylprednisolone chemical raw materials. Methylprednisolone is a medium-acting, halogen-free corticosteroid medication suitable for emergency treatment and management of various diseases, including endocrine disorders, rheumatic diseases, and skin diseases

Zhitong

Sito Bio: The listing application for the chemical raw material drug Methylprednisolone has been approved

According to the Zhitong Finance APP, Sito Bio released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 749 million yuan, a year-on-year decrease of 2.07%. The net loss attributable to shareholders of the listed company was 69.2303 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 72.3879 million yuan. The basic loss per share was 0.36 yuan

Sito Bio released its performance for the first three quarters, with a net loss attributable to the parent company of 69.2303 million yuan

Sito Bio announced that its holding subsidiary, Sray Pharmaceutical, recently received the European Pharmacopoeia suitability certificate for Dexamethasone Sodium Phosphate issued by the European Medicines Agency. The certificate is valid for five years starting from October 1, 2025. Dexamethasone Sodium Phosphate is a corticosteroid primarily used for allergic and autoimmune inflammatory diseases. According to IQVIA data, the global demand for Dexamethasone Sodium Phosphate raw materials is nearly 10 tons in 2024

Sito Bio: Subsidiary Srey Pharmaceuticals received the CEP certificate for Dexamethasone Sodium Phosphate raw materials

According to the Zhitong Finance APP, Sito Bio released its semi-annual report for 2025. During the reporting period, the company achieved operating revenue of 508 million yuan, a year-on-year decrease of 10.39%. The net loss attributable to shareholders of the listed company was 52.6871 million yuan. The net loss attributable to shareholders of the listed company after deducting non-recurring gains and losses was 53.4816 million yuan. The basic loss per share was 0.28 yuan

Sito Bio released its performance for the first half of the year, turning from profit to a loss of 52.6871 million yuan

601010

601127

As of July 18, there were a total of 587 stocks in the Shanghai and Shenzhen markets with main funds experiencing net outflows for 5 consecutive days or more. Sito Bio had the longest duration of net outflows, reaching 21 days; SERES had the largest net outflow amount, totaling 4.144 billion yuan. WFDSJ had the highest proportion of net outflows relative to trading volume, with a decline of 7.77% in the past 6 days

WFDSJ

SERES

Decrypting the stocks with major capital outflow: 587 stocks with a net outflow for 5 consecutive days

Sito Bio's holding subsidiary, Shandong Srui Pharmaceutical Co., Ltd., recently passed the drug GMP compliance inspection and received a qualification notice from the Shandong Provincial Drug Administration. This marks that the company's chemical raw material budesonide complies with the national drug production quality management standards, allowing it to officially produce and sell the product, which helps maintain product quality and production capacity to meet market demand

Sito Bio: The chemical raw material drug Budesonide has passed the GMP compliance inspection

Sito Bio's subsidiary Shandong Sruy Pharmaceutical Co., Ltd. recently received the CEP certificate for Mometasone Furoate Active Pharmaceutical Ingredient from the European Directorate for the Quality of Medicines (EDQM). This drug has strong anti-inflammatory effects and is suitable for inhalants and topical skin medications, primarily used to treat asthma, eczema, neurodermatitis, and more

Sito Bio's subsidiary has obtained the CEP certificate for Mometasone Furoate API

Sito Bio's holding subsidiary, Shandong Sray Pharmaceutical, recently obtained the Certificate of Suitability for European Pharmacopoeia (CEP certificate) issued by the European Medicines Agency for dexamethasone raw materials. Dexamethasone is a synthetic long-acting adrenal corticosteroid widely used in the treatment of autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus, as well as for the adjunctive treatment of allergic diseases and certain acute infections

Sito Bio: Dexamethasone raw material has obtained the European CEP certificate

Sito Bio's holding subsidiary, Shandong Sruy Pharmaceutical Co., Ltd., recently received the notice of approval for the marketing application of Indacaterol Maleate chemical raw material from the National Medical Products Administration. This drug is a long-acting β2-adrenergic agonist, suitable for the maintenance treatment of adult patients with chronic obstructive pulmonary disease (COPD). The marketed dosage forms include inhalation powder aerosol, among others

Sito Bio(300583.SZ)